Since TILs and PD-L1 are part of the BC immune spectrum, the International Immuno-Oncology Biomarker Working Group recommends the systematic implementation of combined PD-L1 and TILs analysis as a more comprehensive immuno-oncology biomarker for screening BC patients PD-1/ PD-L1 inhibitory treatment [31]. The gene discussed is PDCD1; the disease is breast cancer.